TABLE 2.
Phenotypic drug susceptibility testing results for highly drug-resistant M. tuberculosis isolates collected from four multinational sitesa
Study site | Drug resistance (critical concn [mg/liter]) to the indicated antibioticb |
|||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
INH (0.1) |
RIF (1.0) |
MOX (0.25) |
OFX (2.0) |
AMK (1.0) |
CAP (2.5) |
KAN (2.5) |
||||||||
No. of isolates |
No. of isolates |
No. of isolates |
No. of isolates |
No. of isolates |
No. of isolates |
No. of isolates |
||||||||
R | S | R | S | R | S | R | S | R | S | R | S | R | S | |
India | 104 | 7 | 103 | 8 | 98 | 13 | 100 | 11 | 94 | 17 | 88 | 23 | 99 | 12 |
Moldova | 83 | 8 | 80 | 11 | 68 | 23 | 67 | 23 | 31 | 60 | 32 | 59 | 76 | 15 |
Philippines | 88 | 21 | 78 | 33 | 34 | 75 | 35 | 75 | 13 | 98 | 9 | 91 | 16 | 95 |
South Africa | 96 | 7 | 95 | 8 | 92 | 11 | 90 | 13 | 92 | 11 | 90 | 13 | 95 | 8 |
Total | 371 | 43 | 356 | 60 | 292 | 122 | 292 | 122 | 230 | 186 | 219 | 186 | 286 | 130 |
Isolates were screened for phenotypic resistance (R, resistant; S, susceptible) on an MGIT 960 platform using WHO-recommended critical concentrations to define resistance.
INH, isoniazid; RIF, rifampin; MOX, moxifloxacin; OFX, ofloxacin; AMK, amikacin; KAN, kanamycin; CAP, capreomycin.